Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan de Hoon, Williams Smith, Kathryn E. Stephenson, Dan H. Barouch, Stephen C. De Rosa, Kristen W. Cohen, M. Juliana McElrath, Emmanuel Cormier, Gert Scheper, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, Hanneke Schuitemaker
doi: https://doi.org/10.1101/2020.09.23.20199604
Jerald Sadoff
1Janssen Vaccines & Prevention, Leiden, The Netherlands
Mathieu Le Gars
1Janssen Vaccines & Prevention, Leiden, The Netherlands
Georgi Shukarev
1Janssen Vaccines & Prevention, Leiden, The Netherlands
Dirk Heerwegh
2Janssen Research & Development, Beerse, Belgium
Carla Truyers
2Janssen Research & Development, Beerse, Belgium
Anne Marit de Groot
1Janssen Vaccines & Prevention, Leiden, The Netherlands
Jeroen Stoop
1Janssen Vaccines & Prevention, Leiden, The Netherlands
Sarah Tete
1Janssen Vaccines & Prevention, Leiden, The Netherlands
Wim Van Damme
3Janssen Clinical Pharmacology Unit, Merksem, Belgium
Isabel Leroux-Roels
4CEVAC - University of Gent, Gent, Belgium
Pieter-Jan Berghmans
5SGS Life Sciences, Antwerp, Belgium
Murray Kimmel
6Optimal Research LLC, Melbourne, Florida, USA
Pierre Van Damme
8Centre for the Evaluation of Vaccination, University of Antwerp, Antwerp, Belgium
Jan de Hoon
9Center for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium
Williams Smith
10VRG and NOCCR, Knoxville, Tennessee, USA
Kathryn E. Stephenson
11Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA
Dan H. Barouch
11Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA
Stephen C. De Rosa
12Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Kristen W. Cohen
12Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
M. Juliana McElrath
12Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Emmanuel Cormier
1Janssen Vaccines & Prevention, Leiden, The Netherlands
Gert Scheper
1Janssen Vaccines & Prevention, Leiden, The Netherlands
Jenny Hendriks
1Janssen Vaccines & Prevention, Leiden, The Netherlands
Frank Struyf
2Janssen Research & Development, Beerse, Belgium
Macaya Douoguih
1Janssen Vaccines & Prevention, Leiden, The Netherlands
Johan Van Hoof
1Janssen Vaccines & Prevention, Leiden, The Netherlands
Hanneke Schuitemaker
1Janssen Vaccines & Prevention, Leiden, The Netherlands

Data Availability
The data referred to in the manuscript will be available.
Posted September 25, 2020.
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan de Hoon, Williams Smith, Kathryn E. Stephenson, Dan H. Barouch, Stephen C. De Rosa, Kristen W. Cohen, M. Juliana McElrath, Emmanuel Cormier, Gert Scheper, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, Hanneke Schuitemaker
medRxiv 2020.09.23.20199604; doi: https://doi.org/10.1101/2020.09.23.20199604
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan de Hoon, Williams Smith, Kathryn E. Stephenson, Dan H. Barouch, Stephen C. De Rosa, Kristen W. Cohen, M. Juliana McElrath, Emmanuel Cormier, Gert Scheper, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, Hanneke Schuitemaker
medRxiv 2020.09.23.20199604; doi: https://doi.org/10.1101/2020.09.23.20199604
Subject Area
Subject Areas
- Addiction Medicine (228)
- Allergy and Immunology (506)
- Anesthesia (110)
- Cardiovascular Medicine (1245)
- Dermatology (147)
- Emergency Medicine (282)
- Epidemiology (10032)
- Gastroenterology (500)
- Genetic and Genomic Medicine (2464)
- Geriatric Medicine (238)
- Health Economics (480)
- Health Informatics (1647)
- Health Policy (754)
- Hematology (250)
- HIV/AIDS (536)
- Medical Education (253)
- Medical Ethics (75)
- Nephrology (268)
- Neurology (2290)
- Nursing (139)
- Nutrition (352)
- Oncology (1249)
- Ophthalmology (377)
- Orthopedics (134)
- Otolaryngology (226)
- Pain Medicine (158)
- Palliative Medicine (50)
- Pathology (325)
- Pediatrics (734)
- Primary Care Research (282)
- Public and Global Health (4843)
- Radiology and Imaging (843)
- Respiratory Medicine (652)
- Rheumatology (286)
- Sports Medicine (227)
- Surgery (269)
- Toxicology (44)
- Transplantation (125)
- Urology (99)